Bionano Genomics, Inc. (NASDAQ:BNGO)
| Market Cap | $11.50M-51.1% |
| Revenue (ttm) | $31.09M+8.2% |
| Net Income | -$30.11M+22.0% |
| EPS | -$2.68+82.7% |
| Shares Out | 13.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 248,640 |
| Open | $0.90 |
| Previous Close | $0.89 |
| Day's Range | $0.82 - $0.93 |
| 52-Week Range | $0.81 - $2.23 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | $46.50(+5555.56%) |
| Earnings Date | Mar 22, 2027 |
About BNGO
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Bionano Genomics, Inc. Stock Analysis — InsiderScore
Bionano Genomics, Inc. scored higher than 1% of companies evaluated by InsiderBuying, and ranked 57th out of 57 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Bionano Genomics, Inc. bought $4.8K of stock across 1 purchase in the last 90 days, the largest of them $4.8K.
The average purchase added about 100% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 22, 2027Earnings report
$BNGO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BNGO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BNGO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BNGO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BNGO Revenue by Segment or Geography
| Contracted services | $1.80M | 54.52% |
| Rent and facilities | $619.00K | 18.73% |
| Consulting | $418.00K | 12.65% |
| Administrative and other | $162.00K | 4.90% |
| Travel and entertainment | $157.00K | 4.75% |
| Non-inventory materials | $147.00K | 4.45% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BNGO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BNGO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BNGO
| VXFVanguard Extended Market ETF | $159.60K |
| TYNEDirexion Nanotechnology ETF | $44.83K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BNGO’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 earnings show record flow cell sales and positive business update, indicating strong operational momentum for Bionano Genomics.
Recent Insider Activity
Insider Score Trend Over Time
-10.0 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| TYNE | Direxion Nanotechnology ETF | 5.37% |
Weight is the stock’s share of each fund’s holdings.
